NASDAQ · Biotechnology · USD
Oculis Holding AG (OCS) Stock Analysis
Oculis Holding AG (OCS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
OCS Key Statistics
As of Oct 21, 2026Trading
- Open
- $7.54
- Previous Close
- $7.49
- Day's Range
- 7.40–8.02
- 52-Week Range
- 7.11–34.48
- Volume
- 324.10K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.27
Valuation
- Market Cap
- $484.70M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 413.21
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −1.74
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$98.96M
- Shares Outstanding
- 61.59M
- 1-Year Return
- −63.93%
Dividend and dates
- Earnings Date
- November 3, 2026
- Avg Volume
- 264.76K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, OCS closed at $7.87, −63.93% over 1 year.
Oculis Holding AG (OCS) has a market capitalization of $484.70M.
In fiscal 2025, OCS reported revenue of $0.00.
OCS Stock Return by Calendar Year
Oculis Holding AG (OCS) return since May 2021: what $10,000 became
- 1 year
- $10,000 $3,607
- −63.93%
- 5 years
- $10,000 $8,105
- −18.95%
- Since May 2021
- $10,000 $8,113
- −18.87%
If you had invested $10,000 in Oculis Holding AG (OCS) at the close on May 18, 2021, the earliest close on record here, it would have been worth $8,113 at the close on October 21, 2026: −18.87% in total, −3.78% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −60.59% |
| 2025 | +17.47% |
| 2024 | +51.38% |
| 2023 | +11.19% |
| 2022 | +4.23% |
| 2021 (partial year) | −0.10% |
As of October 21, 2026.
OCS Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$98.96M | — |
| 2024 | $0.00 | −$85.78M | — |
| 2023 | $0.00 | −$88.80M | — |
| 2022 | $0.00 | −$38.70M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$81.67M | −$98.96M | — |
| 2024 | $0.00 | — | −$73.20M | −$85.78M | — |
| 2023 | $0.00 | — | −$45.85M | −$88.80M | — |
| 2022 | $0.00 | — | −$32.38M | −$38.70M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
OCS Valuation vs Biotechnology Median
Median of 608 stocks| Metric | OCS | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 413.21 | 13.30 | 31.1x the median |
Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
YahooOculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki
YahooOculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
YahooOculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
YahooOculis Announces Resignation of Lionel Carnot from Board of Directors
YahooAfter Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS)
Yahoo
All 19 articles ↓Show fewer ↑
HC Wainwright & Co. Maintains Buy on Oculis Holding, Raises Price Target to $39
BenzingaOculis Holding AG: Navigating Through Major Trial Setback
SeekingAlphaWall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade
YahooJP Morgan Maintains Overweight on Oculis Holding, Lowers Price Target to $20
BenzingaOculis to Buy Accure's Global Development, Commercial Rights to Privosegtor
YahooOculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
YahooOculis Acquires Accure's Privosegtor And ACT-02 Assets In Deal Worth $3.8M Upfront Cash And Up To 2,050,000 Shares
BenzingaOculis Holding Q2 EPS $(0.20) Beats $(0.48) Estimate, Sales $392.150K Beat $260.000K Estimate
BenzingaOculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates
YahooOculis (NASDAQ:OCS) Beats Q2 Estimates and Advances Late-Stage Neuro-Ophthalmology Pipeline
ChartMillOculis Reports Q2 2026 Financial Results and Provides Company Update
YahooHC Wainwright & Co. Maintains Buy on Oculis Holding, Maintains $26 Price Target
BenzingaOculis To Submit IND For Privosegtor In Acute MS Relapses In Q4 2026, Backed By Positive FDA Pre-IND Guidance And Prior Optic Neuritis Data
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B